2004, Number s2
<< Back Next >>
Arch Cardiol Mex 2004; 74 (s2)
Valvular prostheses. National Institute of Cardiology of México experience
Juárez HA, Campo AJA, Figueroa VJR, Benita BA, Ramos CVH, Chagolla SMA, Vega CCA, Marmolejo HI
Language: Spanish
References: 15
Page: 364-368
PDF size: 54.69 Kb.
ABSTRACT
We revised 3,506 patients that January 1993 to June of 2003 were operated of valvular surgery in Institute National of Cardiology. In this group were put on total 4,130 prostheses, which 2,796 were mechanics and 1,334 biological and of these, 932 were manufactured in the INC. 131 patient were reoperated (3.7%), mainly of the mechanics by thrombosis and in biological valves by fibrosis and calcification. The global mortality was 393 patients (11.2%) that it is similar to that other groups, above all taking into account the type of so deteriorated patients that constitute our group. The follow-up shows that the durability of our biological prostheses in this time lapse, it is very similar what find other groups and that by so much our prostheses is reliable.
REFERENCES
Thourani VH, Weintraub WS, Craver JM, Jones EL, Mahoney EM, Guyton RA: Ten-Year trends in heart valve replacement operations. Ann Thorac Surg 2000; 70: 448-55.
Rahimtoola SH: Choice of prosthetic heart valve for adult patients. Journal of the American College of Cardiology 2003; 41(6): 893-94.
Bortolotii MA, Talenti E, Valfre C, Arbustini E, Valente M, et al: Calcific degeneration as the main cause of porcine bioprosthetic valve dysfunction. Am J Cardiol 1984; 53: 1066-70.
Schryer PJ, Tomasek ER, Starr A, Wrigth J: Anticalcification effect of glutaraldehyde preserved valve tissue for increasing time in glutaraldehyde: In: Bodnar A, Yacoub, editors: Proceedings of the Third International Symposium on Biological and Bioprosthetic valves. New York: Yorke Medical Books; 1986: 471-72.
O’Brien MF, Goldstein S, Walsh S, Black KS, Elkins R, Clark D: The SynerGraft valve: a new acellular (nonglutaraldehyde-fixed) tissue heart valve for autologous recellularization: first experimental studies before clinical implantation. Semin Thorac Cardiovasc Surg 1999; 11(suppl 1): 194-200.
Vyavahare N, Hirsch D, Lerner E, BaskinJ, Bianco R, et al: Prevention of bioprosthetic heart valve calcification by ethanol preincubation: efficacy and mechanisms. Circulation. 1997; 95: 479-88.
Schoen FJ, Levy RJ: Heart valve bioprotheses: antimineralization. Eur J Cardiothoracic Surg 1992; (suppl 1): S91-4.
Gott JP, Chih P, Dorsey L, Jay JL Jett GK, Schoen FJ, et al: Calcification of porcine valves: a successful new method of antimineralization. Ann Thorac Surg 1992; 53: 207-16.
Valente M, Pettenazzo E, GaetanoT, Molin GM, Martignago F, DeGiorgi G, et al: Detoxified glutaraldehyde cross-linked pericadium: tissue preservation and mineralization mitigation in a subcutaneous rat model. J Heart Dis 1998; 7: 283-91.
Carpentier SM, Carpentier AF, Chen L, Shen M, Quintero LJ, Witzel TH: Calcium mitigation in bioprosthetic tissues by Iron pretreatment: the challenge of Iron leaching. Ann Thorac Surg 1995; 60: S332-8.
Abolhoda A, Yu S, Oyarzun JR, McCormick JR, Bogden JD, Gabbay S: Calcification of bovine pericardium: Glutaraldehyde versus no-react biomodification. Ann Thorac Surg 1996; 62: 169-74.
David TE, Feindel CM, Scully HE, Bos J, Rakowsky H: Aortic valve replacement with stentless porcine valves: a ten-year experience. J Heart Valve Dis 1998; 7(3): 250-4.
Northrup WF, Kshettry VR, DuBois KA: Trends in mitral valve surgery in a large multi-surgeon, multi-hospital practice. 1979-1999. J Heart Valve Dis 2003; 12(1): 14-24.
Borger MA, Yau TM, Rao V, Scully HE, David TE: Reoperative mitral valve replacement: importance of preservation of the subvalvular apparatus. Ann Thorac Surg 2002; 74: 1482-7.
Kuwaki K, Tsukamot M, Komatsu K, Morishita K, Sakata J, Abe T: Simultaneous aortic and mitral valve replacement: predictors of adverse outcome. J Heart Valve Dis 2003: 12(2).
Full text